丙型肝炎病毒感染与2型糖尿病相关性研究进展

doi:10.3969/j.issn.1672-5069.2016.02.038

Abstract

Abstract: Hepatitis C virus （HCV） infection is causally associated with diabetes mellitus type Ⅱ（T2DM）. Various mechanisms have been proposed explaining involvement of HCV infection in the process of T2DM occurrence,including the interference of insulin signaling pathway,overexpression of tumor necrosis factor-α,lipid and iron metabolism inbalance,resulting in pancreatic cell damage and so on. T2DM is one of various complications associated with HCV infection. T2DM may result in hepatic steatosis,fibrosis,failure to anti-viral treatment and hepatocellular carcinoma. In this review,we summarize some available information related to HCV infection and T2DM.

Key words: Hepatitis C, Diabetes mellitus type Ⅱ, Insulin resistance, Signaling pathway

Li Ping, Wang Maorong. Hepatitis C virus infection and diabetes mellitus type Ⅱ occurrence[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 253-256.

References

[1] Peres DP,Cheinquer H,Wolf FH,et al. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. Ann Hepatol,2013,12（6）:871-875.
[2] Mehta SH,Brancati F L,Strathdee S A,et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology,2003,38（1）:50-56.
[3] Moucari R,Asselah T,Cazals-Hatem D,et al. Insulin resistance in chronic hepatitis C:association with genotypes 1 and 4, serum HCV RNA level,and liver fibrosis. Gastroenterology,2008,134（2）:416-423.
[4] 赵平,王江滨,焦健. 慢性丙型肝炎患者2型糖尿病并发率调查及其基因型特征分析. 中华肝脏病杂志,2006,14（2）:86-88.
[5] 刘孙琴,董明国,门诚虹,等. 慢性丙型肝炎与2型糖尿病关系研究. 中华实用诊断与治疗杂志,2011,25（1）:83-84.
[6] Sporea I,Sirli R,Hogea C,et al. Diabetes mellitus and chronic HCV infection. Rom J Intern Med,2009,47（2）:141-147.
[7] Laloo D,Walke P,Bhimo T,et al. Seroprevalence of hepatitis C infection in type 2 diabetes mellitus. Indian J Endocrinol Metab,2015,19（2）:296-299.
[8] 韦艳妮,梁能秀,苏齐鉴,等. 丙型肝炎病毒感染与2型糖尿病发病关系的研究. 热带医学,2013,13（1）:17-19.
[9] Ruhl C E,Menke A,Cowie C C,et al. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology,2014,60（4）:1139-1149.
[10] Cusi K. The relationship between hepatitis C virus infection and diabetes:time for a divorce Hepatology,2014,60（4）:1121-1123.
[11] Aytug S,Reich D,Sapiro L E,et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV:a mechanism for increased prevalence of type 2 diabetes. Hepatology,2003,38（6）:1384-1392.
[12] Banerjee S,Saito K,Ait-Goughoulte M,et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol,2008,82（6）:2606-2612.
[13] Bose S K,Shrivastava S,Meyer K,et al. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol,2012,86（11）:6315-6322.
[14] Kawaguchi T,Yoshida T,Harada M,et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol,2004,165（5）:1499-1508.
[15] Pazienza V,Clement S,Pugnale P,et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology,2007,45（5）:1164-1171.
[16] Pawlak K,Mysliwiec M,Pawlak D. Chronic viral hepatitis and iron affect the plasma levels of LIGHT a new member of the TNF superfamily in uraemic haemodialyzed patients. Cytokine,2007,39（3）:201-206.
[17] Knobler H,Zhornicky T,Sandler A,et al. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol,2003,98（12）:2751-2756.
[18] Shintani Y,Fujie H,Miyoshi H,et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology,2004,126（3）:840-848.
[19] Camma C,Bruno S,Di Marco V,et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology,2006,43（1）:64-71.
[20] Machado M V,Oliveira A G,Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol,2011,26（9）:1361-1367.
[21] Castera L,Hezode C,Roudot-Thoraval F,et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C:indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut,2004,53（3）:420-424.
[22] Perlemuter G,Sabile A,Letteron P,et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J,2002,16（2）:185-194.
[23] Kim K H, Hong S P,Kim K,et al. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun,2007,355（4）:883-888.
[24] Petta S,Camma C,Di Marco V,et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int,2011,31（4）:507-515.
[25] 刘阳珍,肖新强,成镀,等. 丙型肝炎病毒非结构蛋白质5A抑制Hepcidin基因表达并促进肝细胞内铁储留. 中华肝脏病杂志,2011,19（12）:894-897.
[26] Huang J,Jones D,Luo B,et al. Iron overload and diabetes risk: a shift from glucose to fatty acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis. Diabetes,2011,60（1）:80-87.
[27] Neri S,Bruno C M,D'Angelo G,et al. Peripancreatic lymphoadenopathy and extrahepatic immunological manifestations in chronic hepatitis C. Eur J Clin Invest,1996,26（8）:665-667.
[28] Sigal SH,Stanca CM,Kontorinis N,et al. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol,2006,101（7）:1490-1496.
[29] Huang YW,Yang SS,Fu SC,et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology,2014,60（3）:807-814.
[30] Elkrief L,Chouinard P,Bendersky N,et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology,2014,60（3）:823-831.
[31] Arase Y, Kobayashi M, Suzuki F,et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology,2013,57（3）:964-973.
[32] Kawaguchi T, Ide T,Taniguchi E,et al. Clearance of HCV improves insulin resistance,beta-cell function,and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol,2007,102（3）:570-576.
[33] Romero-Gomez M,Fernandez-Rodriguez C M,Andrade R J,et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol,2008,48（5）:721-727.
[34] Hsu Y C,Lin J T,Ho H J,et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology,2014,59（4）:1293-1302.
[35] Zhang X,Harmsen W S,Mettler T A,et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology,2014,60（6）:2008-2016.
[36] Chojkier M,Elkhayat H,Sabry D,et al. Pioglitazone decreases hepatitis C viral load in overweight,treatment naive,genotype 4 infected-patients:a pilot study. PLoS One,2012,7（3）:e31516.
[37] Harrison S A,Hamzeh F M,Han J,et al. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology,2012,56（2）:464-473.

Hepatitis C virus infection and diabetes mellitus type Ⅱ occurrence

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[5]	Zhang Ying, Wang Hongyan, Chi Cheng, et al. Cross-talk between Notch and LPS-TLR4-NF-κB inflammatory signaling pathways in LPS-activated HepG2 cells [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 470-473.
[6]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[7]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[8]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[9]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[10]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[11]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[12]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[13]	Mai Jingyin, Chen Tianyang, Ping Jian, et al.. Effects of MiR-384 on SIRT3/FOXO1 signaling pathway in HFFA-induced Hepa1-6 cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 829-832.
[14]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[15]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.